These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17548896)

  • 1. The mechanisms of action for treatments of type 2 diabetes.
    Leahy JJ
    Diabetes Educ; 2007; 33 Suppl 5():101S-4S. PubMed ID: 17548896
    [No Abstract]   [Full Text] [Related]  

  • 2. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
    Mari A; Degn K; Brock B; Rungby J; Ferrannini E; Schmitz O
    Diabetes Care; 2007 Aug; 30(8):2032-3. PubMed ID: 17468345
    [No Abstract]   [Full Text] [Related]  

  • 4. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucagon-like peptide-1: modulator of β-cell dysfunction and death.
    Rondas D; D'Hertog W; Overbergh L; Mathieu C
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():185-92. PubMed ID: 24003936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 and type 2 diabetes: physiology and new clinical advances.
    Combettes MM
    Curr Opin Pharmacol; 2006 Dec; 6(6):598-605. PubMed ID: 16987706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Perspective of new and future treatment of type 2 diabetes].
    Sasaoka T
    Nihon Rinsho; 2012 May; 70 Suppl 3():707-15. PubMed ID: 22768603
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention.
    Karaca M; Magnan C; Kargar C
    Diabetes Metab; 2009 Apr; 35(2):77-84. PubMed ID: 19251449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
    Vilsbøll T; Holst JJ; Knop FK
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):453-62. PubMed ID: 19748063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
    Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [GLP-1 mimetics in clinical studies. Treatment by activation of the GLP-1 receptor].
    Ritzel RA
    Pharm Unserer Zeit; 2010 Mar; 39(2):120-5. PubMed ID: 20196040
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
    Sugii H; Matsumura Y; Inoue A; Horigome H; Matsuzaki K; Shimizu A
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):233-41. PubMed ID: 20948161
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of dysregulated glucagon secretion in type 2 diabetes.
    D'Alessio D
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes.
    Guglielmi C; Del Toro R; Lauria A; Maurizi AR; Fallucca S; Cappelli A; Angeletti S; Lachin JM; Pozzilli P
    Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28371189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Should We Think About the Role of the Brain in Glucose Homeostasis and Diabetes?
    Deem JD; Muta K; Scarlett JM; Morton GJ; Schwartz MW
    Diabetes; 2017 Jul; 66(7):1758-1765. PubMed ID: 28603139
    [No Abstract]   [Full Text] [Related]  

  • 19. [New and older pharmaceuticals influencing insulin secretion].
    Olsovský J
    Vnitr Lek; 2009 Apr; 55(4):421-4. PubMed ID: 19449762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.